Physician profile
Thaddeus Michael Bort
NPI 1407810807
$1,310.85
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $232 · 2021: $148 · 2022: $568 · 2023: $79.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.32 | 2019-2022 | |
| Abbvie INC. | $205.15 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $111.34 | 2020-2022 | |
| Amgen INC. | $91.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $63.04 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $62.42 | 2020-2023 | |
| Lilly USA, LLC | $62.27 | 2019-2022 | |
| Corcept Therapeutics | $44.34 | 2020 | |
| Xeris Pharmaceuticals, INC. | $43.56 | 2021-2022 | |
| Medtronic, INC. | $33.89 | 2022 | |
| Amarin Pharma, INC. | $28.64 | 2020 | |
| Astellas Pharma US INC | $27.62 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.21 | 2019 | |
| Glaxosmithkline, LLC. | $26.12 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.92 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.42 | 2020 | |
| Nestle Healthcare Nutrition INC. | $24.02 | 2021 | |
| Abbott Laboratories | $23.39 | 2019 | |
| Lifescan, INC. | $19.68 | 2019 | |
| Mannkind Corporation | $18.10 | 2022 | |
| Eisai INC. | $16.64 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.38 | 2021 | |
| Allergan, INC. | $12.81 | 2020 | |
| Gilead Sciences, INC. | $12.46 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Bort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.